2-氨甲基-4-(4-氟苄基)吗啉 | 112914-13-3

• 物质功能分类: 医药中间体
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氨甲基-4-(4-氟苄基)吗啉
• 中文别名: 2-氨甲基-4-(4-氟苄基)-吗啉；2-(氨甲基)-4-(4-氟苄基)吗啉
• 英文名称: (4-(4-fluorobenzyl)morpholin-2-yl)methanamine
• 英文别名: 2-aminomethyl-4-(4-fluoro-benzyl) morpholine；[4-(4-fluorobenzyl)morpholin-2-yl]methylamine；4-(4-fluorobenzyl)-2-aminomethylmorpholine；2-Aminomethyl-4-(4-fluorobenzyl)morpholine；[4-[(4-fluorophenyl)methyl]morpholin-2-yl]methanamine
• CAS: 112914-13-3
• 化学式: C₁₂H₁₇FN₂O
• 分子量: 224.278
• InChiKey: JHSPPBBJOLKJDH-UHFFFAOYSA-N

物化性质

• 沸点：
  317.4±27.0 °C(Predicted)
• 密度：
  1.145±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  38.5
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P301+P312+P330
• 危险性描述：
  H302
• 储存条件：
  | 2-8°C |

反应信息

• 作为反应物：
  描述：

  2-氨甲基-4-(4-氟苄基)吗啉 在 palladium on activated charcoal sodium hydroxide 、 氢气 、 三乙胺 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 、 氯仿 、 水 、 甲苯 为溶剂， 反应 25.5h， 生成 1-[2-(氨基甲基)-4-吗啉基]乙酮
  参考文献：
  名称：

  Synthesis and Biological Activity of 4-Amino-5-chloro-2-ethoxy-3-hydroxybenzamides, Metabolites of a New Gastroprokinetic Agent, Mosapride.

  摘要：

  为了确认潜在胃动力药物莫沙普利的小分子代谢产物的提议结构，合成了4-amino-5-chloro-2-ethoxy-3-hydroxy-N-(2-morpholinylmethyl)benzamide (3)和N-(5-oxo-2-morpholinyl)-methyl类似物4。作为共同中间体，通过对2,3-二羟基苯甲醛 (10) 进行区域选择性的乙基化以及对生成的2-乙氧基-3-羟基苯甲醛 (11) 进行后续硝化，合成了2-乙氧基-3-羟基-4-硝基苯甲酸 (15)。关键中间体15转化为苯酰胺3和4。在对分离代谢产物进行酶促处理后，通过与合成化合物的比较确认了它们的结构。这些代谢产物的5-羟色胺4受体结合亲和力低于莫沙普利。

  DOI：

  10.1248/cpb.44.1484
• 作为产物：
  描述：

  <2-(acetylamino)methyl>morpholine acetyl salt 在 盐酸 、 potassium carbonate 、 potassium iodide 作用下， 以 丁酮 为溶剂， 反应 21.0h， 生成 2-氨甲基-4-(4-氟苄基)吗啉
  参考文献：
  名称：

  Novel benzamides as selective and potent gastrokinetic agents. 2. Synthesis and structure-activity relationships of 4-amino-5-chloro-2-ethoxy-N-[[4-(4-fluorobenzyl)-2-morpholinyl]methyl]benzamide citrate (AS-4370) and related compounds

  摘要：

  The title compounds (19-55) with a 4-substituted 2-(aminomethyl) morpholine group were prepared and evaluated for the gastrokinetic activity by determining their effect on gastric emptying of phenol red semisolid meal in rats. Introduction of chloro, fluoro, and trifluoromethyl groups to the benzyl group of the parent compounds 1a and 1b enhanced the activity. Among compounds tested, 4-amino-5-chloro-2-ethoxy-N-[[4-(4-fluorobenzyl)-2-morpholinyl]?? methyl]benzamide (23b) showed the most potent gastic emptying activity (effects on phenol red semisolid meal in rats and mice, and on resin pellets solid meal in rats). The gastrokinetic activity of 23b citrate (AS-4370) compared very favorably with that of cisapride and was higher than that of metoclopramide. In contrast to metoclopramide and cisapride, AS-4370 was free from dopamine D2 receptor antagonistic activity in both in vitro ([H-3]spiperone binding) and in vivo (apomorphine-induced emesis in dogs) tests.

  DOI：

  10.1021/jm00106a023
• 作为试剂：
  描述：

  4-氨基-5-氯-2-乙氧基苯甲酸 、 2-氨甲基-4-(4-氟苄基)吗啉 在 2-氨甲基-4-(4-氟苄基)吗啉 作用下， 生成 枸橼酸莫沙比利
  参考文献：
  名称：

  J. Med. Chem. 1991, 34, 616-624

  摘要：

  DOI：

文献信息

• Pyrimidine derivatives
  申请人：Nisshin Flour Milling Co., Ltd.

  公开号：US05736550A1

  公开（公告）日：1998-04-07

  Pyrimidine derivatives useful as a gastrointestinal prokinetic agent, represented by formula ##STR1## wherein X is O or NR.sup.5, Y is O, S or NR.sup.5 wherein R.sup.5 is a hydrogen atom, a C.sub.1 -C.sub.6 alkyl group or the like; R.sup.1 and R.sup.2 may be the same or different and each is a hydrogen atom, a C.sub.1 -C.sub.6 alkyl group or the like; R.sup.3 is CN, or COOR.sup.6 wherein R.sup.6 is a C.sub.1 -C.sub.6 alkyl group, a C.sub.3 -C.sub.6 cycloalkyl group, an aryl group or the like; R.sup.4 is --SR.sup.7 or --NR.sup.8 R.sup.9 wherein R.sup.7 is a C.sub.1 -C.sub.6 alkyl group; R.sup.8 is a C.sub.1 -C.sub.6 alkyl group or the like; R.sup.9 is a hydrogen atom, a C.sub.1 -C.sub.6 alkyl group or the like, or R.sup.8 and R.sup.9 may represent, together with the nitrogen atom to which they are attached, an N-substituted piperazine ring of formula (X) ##STR2## wherein R.sup.10 represents a C.sub.1 -C.sub.6 alkyl group or the like or a pharmacologically acceptable salt thereof. The above-mentioned compounds are useful as a gastrointestinal prokinetic agent used for the therapy of digestive tract diseases.

  嘧啶衍生物可用作胃肠促动力药物，其化学式表示为##STR1##其中X为O或NR.sup.5，Y为O、S或NR.sup.5，其中R.sup.5为氢原子、C.sub.1 -C.sub.6烷基或类似物；R.sup.1和R.sup.2可以相同也可以不同，每个都是氢原子、C.sub.1 -C.sub.6烷基或类似物；R.sup.3为CN，或COOR.sup.6，其中R.sup.6为C.sub.1 -C.sub.6烷基、C.sub.3 -C.sub.6环烷基、芳基或类似物；R.sup.4为--SR.sup.7或--NR.sup.8 R.sup.9，其中R.sup.7为C.sub.1 -C.sub.6烷基；R.sup.8为C.sub.1 -C.sub.6烷基或类似物；R.sup.9为氢原子、C.sub.1 -C.sub.6烷基或类似物，或R.sup.8和R.sup.9可以与它们连接的氮原子一起表示为化学式(X)的N-取代哌嗪环，其中R.sup.10代表C.sub.1 -C.sub.6烷基或类似物，或其药理学上可接受的盐。上述化合物可用作治疗消化道疾病的胃肠促动力药物。
• Copper‐Catalyzed Deaminative Difluoromethylation
  作者：Xiaojun Zeng、Wenhao Yan、Samson B. Zacate、Aijie Cai、Yufei Wang、Dongqi Yang、Kundi Yang、Wei Liu

  DOI：10.1002/anie.202006048

  日期：2020.9.14

  stable bioisostere of an amino (NH2) group. Therefore, methods that can rapidly convert an NH2 group into a CF2H group would be of great value to medicinal chemistry. We report herein an efficient Cu‐catalyzed approach for the conversion of alkyl pyridinium salts, which can be readily synthesized from the corresponding alkyl amines, to their alkyl difluoromethane analogues. This method tolerates a broad

  二氟甲基（CF 2 H）被认为是氨基（NH 2）基团的亲脂性和代谢稳定的生物等排体。因此，能够将NH 2基快速转化为CF 2 H基的方法对药物化学具有重要的价值。我们在此报告了一种有效的铜催化方法，用于将烷基吡啶鎓盐（可以轻松地从相应的烷基胺合成）转化为其烷基二氟甲烷类似物。该方法可耐受多种官能团，可用于复杂的含氨基药物的后期修饰。
• Broadly Applicable Directed Catalytic Reductive Difunctionalization of Alkenyl Carbonyl Compounds
  作者：Tao Yang、Xianxiao Chen、Weidong Rao、Ming Joo Koh

  DOI：10.1016/j.chempr.2019.12.026

  日期：2020.3

  Catalytic alkene difuntionalization is a convenient platform for introducing complexity in molecules and has wide applications in organic synthesis. Yet a compelling challenge that remains to be solved is the regioselective insertion of two highly functionalized carbon-based moieties, derived from stable and readily available organohalide electrophiles without the need for pre-synthesized organometallic

  催化烯烃的双官能化是在分子中引入复杂性的便利平台，在有机合成中具有广泛的应用。仍然需要解决的一个引人注目的挑战是在稳定的烷基取代基中的C = C键之间选择性地插入两个高度官能化的碳基基团，这些基团来自稳定且易于获得的有机卤化物亲电体，无需预先合成的有机金属试剂烯烃。在这里，我们显示出催化量的廉价镍基催化剂与易于回收的8-氨基喹啉导向基团的组合，可在温和的还原条件下，促进脂肪族烯烃中两种不同的有机卤化物（碘化物和溴化物）的高效定点添加。与以前的研究相比，该方案显示出广泛且互补的官能团耐受性，延伸至芳基烷基化，烯基烷基化和二烷基化转化。该策略的实用性通过生物活性分子的简明合成得到证明。动力学研究和其他对照实验进一步阐明了多组分反应的机理基础。
• Substituted benzamide derivatives, for enhancing gastrointestinal
  申请人：Dainippon Pharmaceutical Co., Ltd.

  公开号：US04870074A1

  公开（公告）日：1989-09-26

  Compounds of the formula: ##STR1## wherein R is hydrogen, alkoxycarbonyl, benzyloxycarbonyl, heteroarylalkyl, phenylalkenyl, or --T--(Y).sub.p --R.sub.6 (wherein T is single bond or alkylene, Y is oxygen, sulfur or carbonyl, R.sub.6 is phenyl, substituted phenyl, naphthyl, or diphenylmethyl, and p is 0 or 1, provided that when T is single bond, p is 0); R.sub.1 is halogen, hydroxy, alkoxy, cycloalkyloxy, alkenyloxy, alkynyloxy, alkoxy interrupted by oxygen or carbonyl, alkylthio, amino, monosubstituted amino, or a substituted alkoxy; R.sub.2 is hydrogen; R.sub.3 is hydrogen, halogen, amino, alkylamino, dialkylamino, alkanoylamino, or nitro; R.sub.4 is hydrogen, halogen, nitro, sulfamoyl, alkylsulfamoyl, or dialkylsulfamoyl; or any two adjacent groups of the R.sub.1, R.sub.2, R.sub.3 and R.sub.4 may combine to form alkylenedioxy, and the remaining two groups are each hydrogen; R.sub.5 is hydrogen or alkyl; X is alkylene; m and n are each 1 or 2; provided that at least one of the groups R.sub.2, R.sub.3 and R.sub.4 is other than hydrogen, and acid addition salts, quaternary ammonium salts and N-oxide derivatives thereof, processes for preparation thereof, and pharmaceutical composition containing the same. Said compounds, salts and N-oxide derivatives thereof show excellent gastrointestinal motility enhancing activity.

  式中R为氢、烷氧羰基、苄氧羰基、杂环烷基、苯基烯基，或--T--(Y).sub.p --R.sub.6（其中T为单键或烷基，Y为氧、硫或羰基，R.sub.6为苯基、取代苯基、萘基或二苯甲基，p为0或1，但当T为单键时，p为0）；R.sub.1为卤素、羟基、烷氧基、环烷氧基、烯基氧基、炔基氧基、被氧或羰基中断的烷氧基、烷基硫醚、氨基、单取代氨基，或取代烷氧基；R.sub.2为氢；R.sub.3为氢、卤素、氨基、烷基氨基、二烷基氨基、烷酰氨基，或硝基；R.sub.4为氢、卤素、硝基、磺酰胺基、烷基磺酰胺基，或二烷基磺酰胺基；或R.sub.1、R.sub.2、R.sub.3和R.sub.4中的任意两个相邻基团可结合形成亚烷二氧基，其余两个基团各为氢；R.sub.5为氢或烷基；X为烷基；m和n各为1或2；但R.sub.2、R.sub.3和R.sub.4中至少有一个基团不是氢，以及其酸盐、季铵盐和N-氧化物衍生物，其制备方法，以及含有它们的药物组合物。所述化合物、盐及其N-氧化物衍生物表现出优异的胃肠动力增强活性。
• Nickel-Catalyzed Deaminative Acylation of Activated Aliphatic Amines with Aromatic Amides via C–N Bond Activation
  作者：Chu-Guo Yu、Yutaka Matsuo

  DOI：10.1021/acs.orglett.9b04497

  日期：2020.2.7

  reductive deaminative cross-electrophile coupling reaction between Katritzky salts and aromatic amides. This work provides examples of the synthesis of various ketones from alkylpyridinium salts, including both primary and secondary alkylamines. Given its mild reaction conditions and high functional group tolerance, this cross-coupling strategy is expected to be useful for late-stage functionalization of

  脂族伯胺的脱氨基官能化具有很大的合成用途。在这里，我们描述了Katritzky盐和芳族酰胺之间的Ni催化的还原性脱氨基交叉亲电子偶联反应。这项工作提供了从烷基吡啶鎓盐（包括伯烷基仲胺和仲烷基胺）合成各种酮的实例。鉴于其温和的反应条件和较高的官能团耐受性，这种交叉偶联策略有望用于复杂化合物的后期官能化。